Findings confirm that NanoBio’s nanoemulsion technology is effective

when used in therapeutic applications and vaccines

NanoBio Corporation announced today that it will present compelling new data in nine presentations that detail key milestones in its clinical and preclinical development programs in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal influenza vaccine during the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC, October 25-28.

The company’s presentation schedule during the conference is detailed below. NanoBio will also exhibit at corporate booth #408.

Sunday, October 26, 2008
11:15 a.m. – 12:15 p.m. A Novel Nanoemulsion Adjuvant Enhancing the Immune Response to β-propiolactone Inactivated Influenza Virus Using a Nasal Route in a Ferret Model, Poster #G-1194

Monday, October 27, 2008
11:15 a.m. – 12:15 p.m. Novel Nanoemulsion NB-001 Permeates Skin by the Follicular Route, Poster #A-1898

11:15 a.m. – 12:15 p.m. NB-002, a Novel Nanoemulsion with Anti-Dermatophyte Activity, Poster #M-2134

11:15 a.m. – 12:15 p.m. Mechanism of Skin Penetration and Distribution of a Novel Nanoemulsion, Poster #M-2135

12:15 p.m. – 1:15 p.m. Safety, Tolerability and Pharmacokinetics of NB-001 in a Phase 2 Dose-Ranging Trial in Subjects with Recurrent Herpes Labialis, Poster #V-3539

12:15 p.m. – 1:15 p.m. NB-001, A Novel Nanoemulsion Active Against Acyclovir (ACV)- and Foscarnet (FOS)-Resistant Herpes Simplex Virus (HSV) 1 and 2, Poster #V-3538

Tuesday, October 28, 2008
9:00 a.m. – 9:15 a.m. Oral Presentation: Subject-Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis, Slide Session # V-3771

11:15 a.m. – 12:15 p.m. Novel Nanoemulsion Antimicrobials Tested Against Nine Gram-Positive Species, Poster #F1-3944

11:15 a.m. – 12:15 p.m. Antimicrobial Activity of Nanoemulsions Tested Against Seven Gram-Negative Species, Poster #F1-3945

About NanoBio:
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat™ technology platform. The company’s lead clinical product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B. Company headquarters and laboratory facilities are located in Ann Arbor, Mich.